[Correspondence] Changes in Paracetamol and Leucovorin Use After a White House Briefing

Why It Matters

The episode highlights how political messaging can rapidly alter clinical practice, affecting drug utilization and patient safety across the health system.

Key Takeaways

• Pregnant women's ED paracetamol orders fell 10% post‑briefing
• No change in paracetamol use among non‑pregnant women
• Child leucovorin prescriptions rose 71% after White House announcement
• Small rises observed for aripiprazole and risperidone later
• Findings illustrate rapid prescribing shifts from political messaging

Pulse Analysis

Political rhetoric has long been a catalyst for sudden changes in medication use, a pattern that resurfaced after the September 2025 White House briefing. By invoking concerns about prenatal acetaminophen and touting leucovorin as a potential autism therapy, senior officials bypassed the usual FDA stakeholder process, echoing earlier episodes such as the Trump‑era promotion of unproven COVID‑19 treatments. This direct appeal to the public and clinicians created a media surge that quickly translated into measurable prescribing shifts, underscoring the power of authoritative messaging in shaping health‑care decisions.

The Cosmos analysis, covering over 294 million patient records, quantifies those shifts. Paracetamol orders in emergency departments dropped 10% among pregnant women—a demographic directly targeted by the briefing—while orders for non‑pregnant women remained stable, suggesting the message resonated primarily with concerns about fetal exposure. In contrast, leucovorin prescriptions for children surged 71%, far outpacing modest upticks in autism‑approved antipsychotics. These patterns likely reflect a mix of heightened patient demand, clinician caution, and the allure of a newly endorsed therapy, even though the evidence linking either drug to autism remains contested.

The broader implications are twofold. First, rapid, non‑evidence‑based endorsements can distort drug utilization, potentially leading to under‑treatment of conditions like fever in pregnancy or unnecessary exposure to off‑label medications. Second, the episode calls for stricter safeguards around public health communications, ensuring that policy statements are grounded in robust scientific review before influencing prescribing. For regulators and health‑system leaders, the lesson is clear: transparent, data‑driven messaging is essential to protect both clinical integrity and patient safety.